Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 7/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5690023 | 0.83 | TMEM97 (0.60) | CXCR3TMEM97SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL5690806 | 0.82 | TMEM97 (0.59) | CXCR3TMEM97SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL5450120 | 0.80 | TMEM97 (0.57) | CXCR3TMEM97SIGMAR1 | |
| SCHEMBL5861658 | 0.80 | MAPT (0.60) | CXCR3TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL5690246 | 0.80 | TMEM97 (0.56) | CXCR3TMEM97SIGMAR1 | |
| SCHEMBL13621174 | 0.78 | FNTA (0.64) | FNTAFNTBCHRM1ALDH1A1KDM4E | |
| SCHEMBL5861502 | 0.77 | TMEM97 (0.58) | CXCR3TMEM97SIGMAR1PARP1ALDH1A1 | |
| SCHEMBL17114833 | 0.76 | CXCR3 (1.00) | CXCR3 | |
| SCHEMBL17114836 | 0.76 | CXCR3 (1.00) | CXCR3 | |
| SCHEMBL5861550 | 0.76 | TMEM97 (0.59) | CXCR3TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101881-B2 | Tetrahydroquinolines | PFIZER INC (US) | 2006-09-05 | — | — | US | claimed |
| US-20040254193-A1 | Novel tetrahydroquinolines | PFIZER INC | 2004-12-16 | — | — | US | claimed |
| US-7101881-B2 | Tetrahydroquinolines | PFIZER INC (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040254193-A1 | Novel tetrahydroquinolines | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254193-A1 | Novel tetrahydroquinolines | HTR5A, SLC18A2, HTR3B | CXCR3 395/4885TMEM97 264/4885SIGMAR1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.